Entrada Therapeutics Inc.
TRDA | NASDAQ
$6.87
+$0.23 (+3.46%)
Sep 22, 2026, 11:52 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -2.96 | 9.82 | -75.45 | -4.85 | -10.70 | -28.51 |
PEG Ratio | 0.01 | -0.01 | 0.81 | -0.07 | -0.12 | 0.35 |
PS Ratio | 16.73 | 3.06 | 3.87 | n/a | n/a | n/a |
PB Ratio | 1.39 | 1.50 | 2.06 | 1.99 | 1.79 | -18.04 |
P/FCF Ratio | -3.28 | -14.43 | 3.72 | -4.38 | -9.64 | -26.84 |
P/OCF Ratio | -3.31 | -15.52 | 3.57 | -4.51 | -10.51 | -29.27 |
OCF/S Ratio | -505.53 | -19.72 | 108.36 | n/a | n/a | n/a |
Debt / Equity Ratio | 0.17 | 0.14 | 0.28 | 0.12 | n/a | n/a |
Quick Ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 |
Current Ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 | 11.89 |
Asset Turnover | 0.07 | 0.40 | 0.27 | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | -36.95 | n/a | n/a |
Return on Equity | -46.96% | 15.31% | -2.76% | -44.51% | -17.13% | 63.93% |
Return on Assets | -38.09% | 12.47% | -1.42% | -37.54% | -16.73% | -60.93% |
Return on Invested Capital | -43.69% | 9.39% | 0.55% | -40.78% | -17.09% | -66.39% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 83.89% | 100% | 100% | n/a | n/a | n/a |
Net Profit Margin | -565.48% | 31.13% | -5.18% | n/a | n/a | n/a |
Pretax Profit Margin | -561.84% | 31.54% | 9.34% | n/a | n/a | n/a |
Operating Profit Margin | -613.66% | 22.30% | -2.45% | n/a | n/a | n/a |
FCF Margin | -509.63% | -21.21% | 104.01% | n/a | n/a | n/a |
EBITDA Margin | -560.17% | 33.33% | 11.55% | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove TRDA